Diagnostic Evaluation and Classification of Death Rattle

1. Clinical Assessment

Initial evaluation of death rattle relies on bedside observation and auscultation to distinguish oropharyngeal secretions from true respiratory distress.

A. Bedside Auscultation Techniques

Position the patient supine with the head elevated 15–30° to allow secretions to pool for easier identification.
Auscultate over the trachea and main bronchi bilaterally, comparing anterior and posterior lung fields.
Characterize the noise by its timing (inspiratory vs. expiratory), intensity (audible only at the ear vs. from 2–3 feet away), and response to repositioning.
Repeat assessments every 1–2 hours to track progression or improvement with interventions.

Clinical Pearl: Quiet Environment

Perform auscultation in a quiet environment. Pause ventilator alarms, televisions, and suctioning to unmask subtle gurgling sounds that might otherwise be missed.

B. Characteristic Features of Secretions-Related Noise

The sound is typically a coarse, non-musical gurgling, distinct from high-pitched inspiratory sounds like stridor.
It originates in the oropharynx and is not reproduced by a forced cough or altered by a bronchodilator challenge.
The noise often increases with passive mouth opening and decreases when the head is turned laterally.
Crucially, the absence of tachypnea, accessory muscle use, or oxygen desaturation helps distinguish it from true dyspnea.

Clinical Pearl: The Head Turn Test

A lateral head turn that immediately reduces the audible noise is a strong confirmation that pooling oropharyngeal secretions are the primary source, rather than deeper bronchial fluid.

C. Distinguishing Type 1 vs. Type 2 Death Rattle

Type 1 (Salivary): Characterized by salivary pooling in the final hours of life. It has an abrupt onset (typically <24 hours before death) and is not associated with signs of infection like fever or leukocytosis.
Type 2 (Bronchial): Involves bronchial secretions accumulating over days. This type may coincide with signs of infection, such as fever or an elevated white blood cell count.
Management Implications: Type 1 is often managed with non-pharmacologic measures alone. Type 2 may prompt targeted diagnostics (e.g., chest X-ray) if treating an underlying infection aligns with the patient’s goals of care.

Clinical Pearl: Avoiding Unnecessary Antibiotics

Clearly differentiating Type 1 from Type 2 death rattle can prevent the administration of unnecessary antibiotics in patients with Type 1 presentations, aligning care with a comfort-focused approach.

2. Role of Laboratory and Imaging

Routine labs and imaging seldom alter comfort-focused care for death rattle. Testing should be reserved for identifying reversible processes that align with established patient goals.

A. Limited Utility of Routine Testing

In imminently dying patients, a complete blood count (CBC), electrolyte panel, or chest radiograph rarely changes the immediate comfort measures for death rattle.
Avoid tests that are unlikely to influence symptom control or that may breach advance directives regarding invasive procedures.
Only order a test if its results will directly alter a treatment consistent with goals of care (e.g., ordering a chest X-ray to confirm pulmonary edema, guiding diuretic use for comfort).

B. Indications for Targeted Imaging

Suspected Pneumonia: If there is suspicion of a lobar consolidation and antibiotic therapy is consistent with the patient’s goals.
Pleural Effusion: If a large effusion is suspected and a thoracentesis is being considered for comfort relief.
Point-of-Care Ultrasound (POCUS): Useful for bedside detection of pleural effusions, avoiding the burden of transporting the patient for a formal radiograph.

Clinical Pearl: Prioritize Portability

When imaging is deemed necessary, choose portable modalities like POCUS or a portable chest X-ray to minimize patient disturbance and maintain a focus on comfort.

C. Contextualizing Tests Within Goals of Care

Always weigh the burden of a test against its potential benefit to comfort. Forego diagnostics if they will neither improve comfort nor respect the patient’s advance directives.
Clearly document decisions to forgo testing in the medical record to ensure the entire care team, including rotating staff, is aligned.
Engage the family in explaining the rationale for limiting tests, reinforcing that the focus is on the patient’s comfort and dignity.

3. Severity and Classification Scales

Structured scales like the Death Rattle Intensity Scale (DRIS), Victoria Respiratory Congestion Scale (VRCS), and Respiratory Distress Observation Scale (RDOS) help quantify secretion burden and distress, but they have recognized limitations.

Comparison of Death Rattle and Respiratory Distress Scales
Scale	Description & Scoring	Clinical Use & Limitations
Death Rattle Intensity Scale (DRIS)	Grades audibility: • 0: Inaudible • 1: Heard at bedside only • 2: Heard across the room • 3: Heard ≥10 ft away	Use: Simple, rapid grading of noise intensity. Limitations: High interobserver variability; score is influenced by ambient noise.
Victoria Respiratory Congestion Scale (VRCS)	Combines visual and auditory cues: • 1: Minimal visible secretions • 2: Wet vocalization (no stethoscope) • 3: Gurgling (stethoscope only) • 4: Rattling audible across room	Use: Grades 3–4 often used as a threshold to consider pharmacologic intervention. Limitations: Still subjective and prone to observer variability.
Respiratory Distress Observation Scale (RDOS)	Scores 8 parameters (e.g., heart rate, nasal flaring, accessory muscle use) on a 0–16 scale.	Use: Validated for detecting true respiratory distress, not just noise. A low score (<4) suggests patient comfort despite audible rattle. Limitations: Does not measure secretion noise itself.

Limitations of Classification Scales

It is critical to recognize the shortcomings of these tools:

Poor Patient Correlation: Due to the patient’s decreased level of consciousness, scale scores correlate poorly with self-reported distress.
Reliability Issues: Observer bias, variations in stethoscope placement, and ambient noise levels can significantly reduce the reliability of audibility-based scales.
Family Distress: Family distress is often driven by the perception of suffering associated with the noise, regardless of the objective scale score.

Clinical Pearl: Combine Scales for a Complete Picture

Use the DRIS or VRCS to quantify the noise and the RDOS to assess for patient distress. This combination allows interventions to be tailored to the patient’s actual comfort rather than reacting to noise alone.

4. Risk Stratification and Decision Algorithms

A systematic approach integrates clinical findings and scale scores to triage non-pharmacologic measures first, reserving pharmacologic agents for refractory cases or when family distress is high.

Figure 1: Decision Algorithm for Death Rattle Management. This algorithm integrates clinical assessment with scoring systems to guide a stepwise approach, prioritizing non-pharmacologic interventions and reserving medication for specific scenarios.

A. Triage for Non-Pharmacologic vs. Pharmacologic Management

First-Line (Non-Pharmacologic): Always begin with repositioning the patient (e.g., lateral or semi-prone), limiting oral fluids, providing gentle oropharyngeal suctioning (avoiding deep suctioning), and educating the family about the nature of the sounds.
Second-Line (Pharmacologic): Consider anticholinergic agents (e.g., scopolamine butylbromide, glycopyrrolate) only if the noise persists at a high level (DRIS/VRCS ≥ 3) after non-pharmacologic measures have been attempted, and family distress remains high despite reassurance and education.

B. Escalation Triggers and Documentation

Trigger: Initiate a trial of pharmacologic therapy after at least two documented repositioning or suctioning attempts have failed to reduce the noise level.
Documentation: Use a standardized note template to ensure clear communication across shifts. This should include:
- Current DRIS/VRCS and RDOS scores.
- Specific non-pharmacologic measures that were tried.
- Key points from the family discussion.
- The planned reassessment interval after any intervention.

Clinical Pearl: Structured Documentation

Using a standardized note template (e.g., “Death Rattle Assessment: DRIS [score], RDOS [score], Interventions [list], Next Steps [plan]”) ensures consistency across shifts, promotes evidence-based practice, and reduces the risk of unnecessary or premature anticholinergic use.

References

Moons L et al. Death rattle: current experiences and non-pharmacological management—a narrative review. Ann Palliat Med. 2024;13(1):150–161.
Heisler M et al. Randomized double-blind trial of sublingual atropine vs placebo for the management of death rattle. J Pain Symptom Manage. 2013;45(1):14–22.
Lokker ME et al. Prevalence, impact, and treatment of death rattle: a systematic review. J Pain Symptom Manage. 2014;47(1):105–22.
Campbell ML, Yarandi HN. Death rattle is not associated with patient respiratory distress: is pharmacologic treatment indicated? J Palliat Med. 2013;16(10):1255–59.
Zhuang Q et al. Validity, reliability, and diagnostic accuracy of the Respiratory Distress Observation Scale. J Pain Symptom Manage. 2019;57(2):304–10.e1.
Hirsch CA et al. Influences on the decision to prescribe anticholinergics for death rattle: a focus group study. Palliat Med. 2013;27(8):732–38.
van Esch HJ et al. Effect of prophylactic scopolamine butylbromide on death rattle: the SILENCE trial. JAMA. 2021;326(12):1268–76.
Wee B, Hillier R. Interventions for noisy breathing in patients near to death. Cochrane Database Syst Rev. 2008;(1):CD005177.
Shimizu Y et al. Care strategy for death rattle: survey of bereaved family perceptions. J Pain Symptom Manage. 2014;48(1):2–12.
Yamaguchi T et al. Anticholinergic drugs for death rattle: multicentre prospective cohort study. BMJ Support Palliat Care. 2023;13(4):462–71.

Objective